A question about whether federal preemption precludes challenges to the safety and labeling of drugs available under a Food and Drug Administration OTC monograph won’t be answered in litigation alleging acetaminophen labeling fails to warn about potential risks.
Dismissal of testimony from experts for plaintiffs alleging that prenatal use of Tylenol or other acetaminophen oral products is linked autism and/or attention-deficit hyperactivity disorder in children likely will lead...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?